These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

782 related items for PubMed ID: 36414938

  • 1. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G, Alquier L, Davis K, Bodard A, Williams A, Van Tongel M, Thoret-Bauchet F, Omar SV, Bakare N.
    BMC Infect Dis; 2022 Nov 21; 22(1):870. PubMed ID: 36414938
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L.
    Expert Rev Anti Infect Ther; 2020 May 21; 18(5):475-483. PubMed ID: 32186925
    [Abstract] [Full Text] [Related]

  • 4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 21; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 5. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Padanilam X, Romero R, Te Riele J, Conradie F.
    Lancet Respir Med; 2018 Sep 21; 6(9):699-706. PubMed ID: 30001994
    [Abstract] [Full Text] [Related]

  • 6. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    Eur Respir J; 2016 Feb 21; 47(2):564-74. PubMed ID: 26647431
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V, Mandal A, Dev P, Merker M, Barilar I, Utpatel C, Nilgiriwala K, Rodrigues C, Crook DW, CRyPTIC Consortium, Rasigade JP, Wirth T, Mistry N, Niemann S.
    Genome Med; 2022 Aug 22; 14(1):95. PubMed ID: 35989319
    [Abstract] [Full Text] [Related]

  • 10. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
    Ismail NA, Omar SV, Moultrie H, Bhyat Z, Conradie F, Enwerem M, Ferreira H, Hughes J, Joseph L, Kock Y, Letsaolo V, Maartens G, Meintjes G, Ngcamu D, Okozi N, Padanilam X, Reuter A, Romero R, Schaaf S, Te Riele J, Variava E, van der Meulen M, Ismail F, Ndjeka N.
    Lancet Infect Dis; 2022 Apr 22; 22(4):496-506. PubMed ID: 34780706
    [Abstract] [Full Text] [Related]

  • 11. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
    Kherabi Y, Fréchet-Jachym M, Rioux C, Yazdanpanah Y, Méchaï F, Pourcher V, Robert J, Guglielmetti L, MDR-TB Management Group.
    Emerg Infect Dis; 2022 Sep 22; 28(9):1796-1804. PubMed ID: 35997386
    [Abstract] [Full Text] [Related]

  • 12. A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.
    Shim TS, Pai H, Mok J, Lee SH, Kwon YS, Choi JC, Park J, Birmingham E, Mao G, Alquier L, Davis K, Thoret-Bauchet F, Kim JH, Kim H, Bakare N.
    BMC Infect Dis; 2023 Jan 09; 23(1):15. PubMed ID: 36624432
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates.
    Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, Metchock B, Miliauskas S, Viet Nhung N, Rodrigues C, Shin S, Simsek H, Smithtikarn S, Ngoc ALT, Boonyasopun J, Kazi M, Kim S, Kamolwat P, Musteikiene G, Sacopon CA, Tahseen S, Vasiliauskaitė L, Wu MH, Vally Omar S.
    J Clin Microbiol; 2022 Jan 19; 60(1):e0291920. PubMed ID: 34705538
    [Abstract] [Full Text] [Related]

  • 17. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, Padanilam X, Reuter A, Romero R, Ismail F, Enwerem M, Ferreira H, Conradie F, Naidoo K, Menzies D.
    Lancet Infect Dis; 2022 Jul 19; 22(7):1042-1051. PubMed ID: 35512718
    [Abstract] [Full Text] [Related]

  • 18. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.
    Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R, Limberis J, Sirgel F, Dolby T, Spies C, Reuter A, Folkerts M, Allender C, Lemmer D, Van Rie A, Gagneux S, Rigouts L, Te Riele J, Dheda K, Engelthaler DM, Warren R, Metcalfe J, Cox H, Theron G.
    Lancet Microbe; 2023 Dec 19; 4(12):e972-e982. PubMed ID: 37931638
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
    Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C.
    Emerg Infect Dis; 2019 May 19; 25(5):936-943. PubMed ID: 31002070
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.